Geltor key facts
as of Oct 2026- Producer of bespoke animal-free proteins intended to advance protein innovation.
- Geltor is valued at approximately $462.9M as of Oct 2026 (last reported valuation).
- It has raised $112.8M; the latest was Later Stage VC in Aug 2025.
- Notable investors include SOSV, BoxGroup, IndieBio, Texas Medical Center, Pegasus Tech Ventures — 44 tracked in total.
- Status: Privately Held (backing).
Geltor's last reported valuation, Feb 2022. Nothing priced has surfaced since.
- ·The complete investor list: 44 names
- ·Watch Geltor: the Monday email on marks, rounds and moves
Geltor funding rounds
No funding rounds for Geltor are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Geltor
44+Membership and data by Private Market View
Geltor valuation
Geltor's last reported valuation was $463 million in Feb 2022. No priced round, secondary trade or fund mark has surfaced since.
Geltor investors
44 investors are on record for Geltor, including SOSV, BoxGroup, IndieBio and Texas Medical Center. By type, the record holds 17 venture capital firms and 4 family offices.
About Geltor
Producer of bespoke animal-free proteins intended to advance protein innovation. The company's products feature a proprietary AI that designs novel proteins by narrowing down amino acid sequences from extended possibilities, creating customized proteins for industries focused on beauty, health, and other applications that require specialized proteins tailored to specific functional and commercial requirements, enabling businesses to make products sustainably and grow towards a plant-based future.
- Sector
- Healthcare
- HQ
- Emeryville, CA, United States
- Founded
- 2015
- Employees
- 50
- Website
- geltor.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.